Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Sridevi Rajeeve

Memorial Sloan Kettering Cancer Center

United States

Research Interests

Explore related searches

Articles (20)

Collaborators (3)

Gunjan Shah

Memorial Sloan Kettering Cancer Center

UNITED STATES

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sridevi Rajeeve

Research Interests

Explore related searches

Articles (20)

Collaborators (3)

Gunjan Shah

Saad Usmani

Francesco Maura

Make your next move.

Sridevi Rajeeve

Research Interests

Explore related searches

Articles (20)

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma

Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel in patients with multiple myeloma

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

Addition of elotuzumab to backbone treatment regimens for multiple myeloma: an updated meta-analysis of randomized clinical trials

Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma

The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma

Bendamustine Bridging Versus Standard of Care Chemotherapy on Toxicity Profile for Multiple Myeloma Patients Undergoing CAR T Cell Therapy

Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma

Clinical Outcomes Associated with Del( 17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Collaborators (3)

Gunjan Shah

Saad Usmani

Francesco Maura

Make your next move.